

Elke De Bruyne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9102071/publications.pdf>

Version: 2024-02-01

88
papers

2,912
citations

136740

32
h-index

182168

51
g-index

91
all docs

91
docs citations

91
times ranked

4637
citing authors

#	ARTICLE	IF	CITATIONS
1	Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 904.	1.8	25
2	Pyroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 45.	3.5	13
3	System Xc ⁻ inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance. <i>Cancer Letters</i> , 2022, 535, 215649.	3.2	11
4	A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma. <i>Cell Death and Disease</i> , 2021, 12, 167.	2.7	12
5	C9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death. <i>Blood Advances</i> , 2021, 5, 2325-2338.	2.5	19
6	Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma. <i>Clinical Epigenetics</i> , 2021, 13, 174.	1.8	11
7	Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects By Inhibiting c-Myc Expression in Vitro and In Vivo. <i>Blood</i> , 2021, 138, 1594-1594.	0.6	1
8	Pyroline-5-Carboxylate Reductase 1: A Novel Target for Sensitizing Myeloma to Cytotoxic Agents By Inhibition of PRAS40-Mediated Protein Synthesis. <i>Blood</i> , 2021, 138, 1574-1574.	0.6	0
9	Kinome expression profiling to target new therapeutic avenues in multiple myeloma. <i>Haematologica</i> , 2020, 105, 784-795.	1.7	33
10	AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma. <i>Cancers</i> , 2019, 11, 1727.	1.7	18
11	The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma. <i>Frontiers in Genetics</i> , 2019, 10, 740.	1.1	5
12	The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma. <i>British Journal of Cancer</i> , 2019, 120, 1137-1146.	2.9	12
13	Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 87.	2.8	7
14	The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma. <i>Cancers</i> , 2019, 11, 1823.	1.7	36
15	Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway. <i>Cancer Letters</i> , 2019, 442, 233-241.	3.2	49
16	The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma. <i>Blood</i> , 2019, 134, 3058-3058.	0.6	2
17	MCL1 Inhibitors in Multiple Myeloma. <i>Blood</i> , 2019, 134, SCI-12-SCI-12.	0.6	1
18	Receptor Tyrosine Kinase AXL: A Potential Strategy to Counter Immune Suppression and Dormancy in Multiple Myeloma. <i>Blood</i> , 2019, 134, 4335-4335.	0.6	0

#	ARTICLE	IF	CITATIONS
19	DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. <i>British Journal of Cancer</i> , 2018, 118, 1062-1073.	2.9	30
20	Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression. <i>Cancer Research</i> , 2018, 78, 1155-1168.	0.4	27
21	Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. <i>Blood Cancer Journal</i> , 2018, 8, 105.	2.8	113
22	The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response. <i>Frontiers in Oncology</i> , 2018, 8, 566.	1.3	39
23	The genetic landscape of 5T models for multiple myeloma. <i>Scientific Reports</i> , 2018, 8, 15030.	1.6	15
24	Metabolic Features of Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1200.	1.8	53
25	Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects. <i>Oncolmmunology</i> , 2018, 7, e1484981.	2.1	26
26	Abstract 2120: Inhibition of multiple myeloma exosomes prevents bone loss and reduces tumor growth. , 2018, , .		0
27	Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development. <i>Blood</i> , 2018, 132, 4484-4484.	0.6	3
28	Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition. <i>Haematologica</i> , 2017, 102, e266-e270.	1.7	28
29	Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma. <i>Leukemia</i> , 2017, 31, 2678-2685.	3.3	25
30	RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. <i>Leukemia</i> , 2017, 31, 1706-1714.	3.3	49
31	Tumour-associated macrophage-mediated survival of myeloma cells through <scp>STAT3</scp> activation. <i>Journal of Pathology</i> , 2017, 241, 534-546.	2.1	50
32	Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. <i>Cancer Immunology Research</i> , 2017, 5, 839-846.	1.6	41
33	The therapeutic potential of cell cycle targeting in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 90501-90520.	0.8	39
34	Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells. <i>Oncotarget</i> , 2017, 8, 52016-52025.	0.8	5
35	Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 38927-38945.	0.8	53
36	Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. <i>Cancer Letters</i> , 2016, 377, 17-24.	3.2	106

#	ARTICLE	IF	CITATIONS
37	RAS Association Domain Family Member 4 (RASSF4): A New Potent Tumor Suppressor in Multiple Myeloma. <i>Blood</i> , 2016, 128, 2057-2057.	0.6	1
38	Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients. <i>PLoS ONE</i> , 2016, 11, e0154256.	1.1	8
39	Novel strategies to target the ubiquitin proteasome system in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 6521-6537.	0.8	66
40	Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. <i>Oncotarget</i> , 2016, 7, 4062-4076.	0.8	33
41	The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential. <i>Oncotarget</i> , 2016, 7, 48732-48752.	0.8	40
42	The Crosstalk Between Leptin Receptor Activation and iNKT Mediated Anti-Tumor Immunity in Multiple Myeloma. <i>Blood</i> , 2016, 128, 2075-2075.	0.6	0
43	Targeting S100A9 Interactions in the Multiple Myeloma Bone Marrow Environment Reduces Angiogenesis and Tumor Growth. <i>Blood</i> , 2016, 128, 3248-3248.	0.6	0
44	SET8 Is a Potential Therapeutic Target in MM. <i>Blood</i> , 2016, 128, 4435-4435.	0.6	0
45	Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells. <i>Oncotarget</i> , 2015, 6, 10532-10547.	0.8	64
46	The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. <i>Oncotarget</i> , 2015, 6, 43992-44004.	0.8	127
47	<i>In vivo</i> treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. <i>Oncotarget</i> , 2015, 6, 3319-3334.	0.8	25
48	Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. <i>Leukemia</i> , 2014, 28, 444-447.	3.3	68
49	Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma. <i>Cancers</i> , 2014, 6, 1363-1381.	1.7	68
50	Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. <i>Blood</i> , 2014, 124, 555-566.	0.6	371
51	Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies. <i>Frontiers in Oncology</i> , 2014, 4, 349.	1.3	92
52	Stimulation of invariant natural killer T cells by Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model. <i>British Journal of Haematology</i> , 2014, 167, 651-663.	1.2	12
53	Myeloid Derived Suppressor Cell Mediated AMPK Activation Regulates Multiple Myeloma Cell Survival. <i>Blood</i> , 2014, 124, 2009-2009.	0.6	3
54	The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. <i>Oncotarget</i> , 2014, 5, 3115-3129.	0.8	48

#	ARTICLE	IF	CITATIONS
55	The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic. <i>Oncotarget</i> , 2014, 5, 11193-11208.	0.8	15
56	The in vivo Transcriptional Response Towards Epigenetic Modulating Agents in Multiple Myeloma. <i>Blood</i> , 2014, 124, 3375-3375.	0.6	0
57	Targeting the Anaphase Promoting Complex/Cyclosome (APC/C) in Multiple Myeloma. <i>Blood</i> , 2014, 124, 2097-2097.	0.6	1
58	Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, <i>In Vivo</i> and <i>In Vitro</i> . <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1763-1773.	1.9	48
59	Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma. <i>Cancers</i> , 2013, 5, 430-461.	1.7	43
60	Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma Model. <i>PLoS ONE</i> , 2013, 8, e65075.	1.1	24
61	Epigenetic Regulation of Myeloma Within Its Bone Marrow Microenvironment. , 2013, , 255-282.		0
62	The Role of Notch Signaling in Multiple Myeloma. , 2013, , 77-95.		1
63	Bone Marrow Stromal Cell-Derived Exosomes Facilitate Multiple Myeloma Cell Survival Through Inhibition Of The JNK Pathway. <i>Blood</i> , 2013, 122, 679-679.	0.6	0
64	The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin. <i>Clinical Cancer Research</i> , 2012, 18, 2230-2239.	3.2	16
65	Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. <i>Leukemia</i> , 2012, 26, 2424-2428.	3.3	67
66	Tumor-initiating capacity of CD138 ^{hi} and CD138 ⁺ tumor cells in the 5T33 multiple myeloma model. <i>Leukemia</i> , 2012, 26, 1436-1439.	3.3	31
67	Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138 ⁺ MM-cell proliferation. <i>Leukemia</i> , 2012, 26, 1402-1405.	3.3	42
68	Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. <i>DMM Disease Models and Mechanisms</i> , 2012, 5, 763-771.	1.2	51
69	Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition. <i>Blood</i> , 2012, 119, 826-837.	0.6	78
70	Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. <i>Biochemical and Biophysical Research Communications</i> , 2012, 428, 518-524.	1.0	47
71	Preclinical Evaluation of Invariant Natural Killer T-Cells in the 5T33 Multiple Myeloma Model. <i>Blood</i> , 2012, 120, 938-938.	0.6	0
72	Dll1/Notch Interaction Contributes to a Decreased Sensitivity of Myeloma Cells to Bortezomib. <i>Blood</i> , 2012, 120, 1840-1840.	0.6	0

#	ARTICLE	IF	CITATIONS
73	The Microenvironment and Molecular Biology of the Multiple Myeloma Tumor. <i>Advances in Cancer Research</i> , 2011, 110, 19-42.	1.9	61
74	IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. <i>Blood</i> , 2010, 115, 2430-2440.	0.6	88
75	Thymosin β 4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. <i>Haematologica</i> , 2010, 95, 163-167.	1.7	22
76	Large double copy vectors are functional but show a size-dependent decline in transduction efficiency. <i>Journal of Biotechnology</i> , 2010, 150, 37-40.	1.9	23
77	The Effects of Forodesine in Murine and Human Multiple Myeloma Cells. <i>Advances in Hematology</i> , 2010, 2010, 1-8.	0.6	4
78	Involvement of Dll1/Notch Interaction In MM Drug Resistance, Clonogenic Growth and In Vivo Engraftment. <i>Blood</i> , 2010, 116, 2966-2966.	0.6	0
79	Epigenetic Regulation of Multiple Myeloma Within its Bone Marrow Microenvironment. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S29-S30.	1.4	1
80	In Search of the Most Suitable Lentiviral shRNA System. <i>Current Gene Therapy</i> , 2009, 9, 192-211.	0.9	16
81	Epigenetic Silencing of the Tetraspanin CD9 during Disease Progression in Multiple Myeloma Cells and Correlation with Survival. <i>Clinical Cancer Research</i> , 2008, 14, 2918-2926.	3.2	46
82	Decreased Thymosin β 4 Expression Results in Poor Prognosis and Decreased Survival in Multiple Myeloma. <i>Blood</i> , 2008, 112, 1703-1703.	0.6	0
83	Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells. <i>Current Immunology Reviews</i> , 2007, 3, 41-55.	1.2	6
84	Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. <i>Leukemia</i> , 2007, 21, 1580-1584.	3.3	124
85	Regulation of Bim Expression by IGF-1 in the 5T33MM Murine Model for Multiple Myeloma. <i>Blood</i> , 2007, 110, 3512-3512.	0.6	2
86	Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients. <i>Leukemia</i> , 2006, 20, 1870-1879.	3.3	24
87	Multifunctional Role of Matrix Metalloproteinases in Multiple Myeloma. <i>American Journal of Pathology</i> , 2004, 165, 869-878.	1.9	44
88	Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3